Adipogenesis and fat-cell function in obesity and diabetes

Trends in Molecular Medicine

Volumn 8, Issue 9, 2002, Pages 442-447

  Camp, Heidi S ^a   Ren, Delin ^a   Leff, Todd ^b  

^a PFIZER INC   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; DIABETES MELLITUS; HOMEOSTASIS; HUMAN; LIPID STORAGE; METABOLIC BALANCE; METABOLIC DISORDER; NONHUMAN; OBESITY; REVIEW;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; CELL DIFFERENTIATION; DIABETES MELLITUS; HUMANS; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0036730527     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02396-1     Document Type: Review

References (65)

1. The continuing epidemics of obesity and diabetes in the United States
2. Deterioration of the metabolic risk profile in women. Respective contributions of impaired glucose tolerance and visceral fat accumulation
3. Lipotoxic diseases
4. Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia
5. Activation of peroxisome proliferator-activated receptor γ bypasses the function of the retinoblastoma protein in adipocyte differentiation
6. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs
7. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F
8. Role of PPARγ in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis
9. Analysis of cell cycle arrest in adipocyte differentiation
10. Molecular regulation of adipogenesis
11. The role of C/EBP genes in adipocyte differentiation
12. Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of Leucine zipper proteins
13. Role of the CCAAT/enhancer-binding protein-α transcription factor in the glucocorticoid stimulation of p21waf1/cip1 gene promoter activity in growth-arrested rat hepatoma cells
14. Retinoic acid blocks adipogenesis by inhibiting C/EBPβ-mediated transcription
15. Modulation of the murine peroxisome proliferator-activated receptor 2γ promoter activity by CCAAT/enhancer-binding proteins
16. Defective adipocyte differentiation in mice lacking the C/EBPβ and/or C/EBPδ gene
17. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: Alternative promoter use and different splicing yield two mPPARγ isoforms
18. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: No alteration in adipose tissue of obese and NIDDM patients
19. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa
20. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
21. PPARγ knockdown by engineered transcription factors: Exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis
22. Ligand-independent activation domain in the N-terminus of peroxisome proliferator-activated receptor γ (PPARγ). Differential activity of PPARγ1 and -2 isoforms and influence of insulin
23. PPARγ induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via downregulation of PP2A
24. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
25. PPARγ is required for placental, cardiac, and adipose tissue development
26. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro
27. Impaired energy homeostasis in CEBPA-knockout mice
28. Cross-regulation of C/EBPα and PPARγ controls the transcriptional pathway of adipogenesis and insulin sensitivity
29. Ectopic expression of the CCAAT/enhancer-binding protein α promotes the adipogenic program in a variety of mouse fibroblastic cells
30. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
31. C/EBPα induces adipogenesis through PPARγ: A unified pathway
32. Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPARγ and C/EBPα
33. Peroxisome proliferator-activated receptor γ and metabolic disease
34. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
35. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance
36. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance
37. Effect of troglitazone on body fat distribution in type 2 diabetic patients
38. Efficacy of troglitazone on body fat distribution in type 2 diabetes
39. Postreceptor defects causing insulin resistance in normoinsulinemic non-insulin-dependent diabetes mellitus
40. Visceral adiposity and risk of type 2 diabetes: A prospective study among Japanese Americans
41. The antidiabetic PPARγ ligand: Update on compunds in development
42. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy
43. A novel heterozygous mutation in peroxisome proliferator-activated receptor γ gene in a patient with familial partial lipodystrophy
44. Insulin resistance in human partial lipodystrophy
45. Positional cloning of the mouse obese gene and its human homologue
46. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
47. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ
48. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance
49. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance
50. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells
51. Effects of an engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM
52. A novel serum protein similar to C1q, produced exclusively in adipocytes
53. AdipoQ is a novel adipose-specific gene dysregulated in obesity
54. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin
55. Genomewide search for type 2 diabetes-susceptibility genes in French whites: Evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome q21-q24
56. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome
57. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice
58. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
59. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
60. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients
61. Induction of adipocyte complement-related protein of 30 kDa by PPARγ agonists: A potential mechanism of insulin sensitization
62. Resistin and obesity-associated insulin resistance
63. The hormone resistin links obesity to diabetes
64. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor γ agonists
65. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans